USPTO serial 88171179
CIPLA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 29, 2019
- Examiner
- NITKIN, DINISHA F
- Law office
- Historical data usage
What this means
Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary. Calendar the 10-year Section 8 and 9 combined renewal.
Need help with CIPLA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Mumbai, Maharashtra, IN
Mumbai, Maharashtra, IN
Mumbai, Maharashtra, IN
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Stacey R. Halpern
Stacey R. Halpern Knobbe, Martens, Olson & Bear, LLP2040 Main Street, 14th FloorIrvine, CA 92614United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and medicinal preparations for the treatment, alleviation and prevention of gastro-intestinal disorders, disorders of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, seizures Huntington's disease, multiple sclerosis; Pharmaceutical and medicinal preparations for the treatment, alleviation and prevention of disorders of the respiratory system, heart conditions and other disorders of the cardiovascular system, namely, Coronary artery disease, Heart attack, abnormal heart rhythms, arrhythmias, heart failure, heart valve disease, congenital heart disease, cardiomyopathy, pericardial disease; Pharmaceutical and medicinal preparations for the treatment, alleviation and prevention of migraines and other forms of headache, namely, sinus headaches, tension headaches, cluster headaches and rebound headaches; pharmaceutical and medicinal preparations, namely, analgesics; pharmaceutical and medicinal preparations, namely, antiviral and anti-retroviral pharmaceutical preparations for the treatment of viral brain diseases; pharmaceutical and medicinal preparations, namely, anti-infectives; pharmaceutical and medicinal preparations, namely, anti-inflammatories; pharmaceutical and medicinal preparations, namely, antibiotics; pharmaceutical and medicinal preparations, namely, antidepressants; pharmaceutical and medicinal preparations, namely, anti-cancer preparations; pharmaceutical and medicinal preparations, namely, medicated soaps and lotions for the skin and hair, namely, medicated acne lotion, medicated body moisturizing lotion, medicated lotion for eczema and seborrheic dermatitis, medicated hair shampoo and hair scalp lotion, medicated anti-dandruff lotion; pharmaceutical and medicinal preparations, namely, decongestants and antihistamines; pharmaceutical and medicinal preparations, namely, scabicides; pharmaceutical and medicinal preparations, namely, anti-malarials; pharmaceutical and medicinal preparations, namely, cough suppressants; pharmaceutical and medicinal preparations, namely, cough and cold preparations; pharmaceutical and medicinal preparations, namely, expectorants; pharmaceutical and medicinal preparations, namely, anti-leukemic agents; pharmaceutical and medicinal preparations, namely, tissue sealants; pharmaceutical and medicinal preparations, namely, vasopressors; pharmaceutical and medicinal preparations, namely, nondepolarizing skeletal neuromuscular blocking agents; pharmaceutical and medicinal preparations, namely, preparations for the treatment of gout; pharmaceutical and medicinal preparations, namely, preparations for cessation of smoking; Pharmaceutical and medicinal preparations for the treatment, alleviation and prevention of genitourinary diseases and disorders, namely, urological diseases, urological disorders, urinary incontinence, infertility, sexually transmitted diseases, inflammatory pelvic diseases; Pharmaceutical and medicinal preparations for the treatment, alleviation and prevention of pain from burns, hemolytic diseases and disorders, neuropathic pain; Pharmaceutical and medicinal preparations for the treatment, alleviation and prevention of fibromyalgia, post-herpetic neuralgia, chronic pain, obesity, inflammation and inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, immunological diseases and disorders, namely, autoimmune diseases, immunologic deficiency syndromes, Acquired Immune Deficiency Syndrome (AIDS), viral diseases and disorders, namely, herpes, hepatitis, substance abuse disorders, namely, alcoholism and drug addiction, carpel tunnel syndrome, varicose veins, dental and oral diseases, osteoporosis, arthritis, yeast infections, prostate disorders, pulmonary disorders, sleep disorders, namely, insomnia and, restless leg syndrome, premature ejaculation, macular degeneration, thrombosis and thromboembolism; pharmaceutical and medicinal preparations, namely, vaccines for human use; pharmaceutical and medicinal preparations, namely, adjuvants for use with human vaccines; pharmaceutical and medicinal preparations in the nature of veterinary preparations, namely, flea and tick preparations, vaccines, anti inflammatories, mastitis preparations, and oncological preparations | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 10, 2026 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Apr 10, 2026 | 8.OK | REGISTERED - SEC. 8 (6-YR) ACCEPTED | The USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline. |
| Mar 20, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 29, 2025 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Oct 29, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Oct 29, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 13, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 13, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 24, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 8, 2019 | ALIE | ASSIGNED TO LIE | — |
| Jun 27, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 27, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 27, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 27, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 27, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 7, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 6, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 6, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 4, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 4, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 4, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 4, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 9, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 30, 2018 | NWAP | NEW APPLICATION ENTERED | — |